PT  - JOURNAL ARTICLE
AU  - Mary Ni Lochlainn
AU  - Karla A. Lee
AU  - Carole H. Sudre
AU  - Thomas Varsavsky
AU  - M. Jorge Cardoso
AU  - Cristina Menni
AU  - Ruth C. E. Bowyer
AU  - Long H. Nguyen
AU  - David A. Drew
AU  - Sajaysurya Ganesh
AU  - Julien Lavigne du Cadet
AU  - Alessia Visconti
AU  - Maxim B. Freidin
AU  - Marc Modat
AU  - Mark S Graham
AU  - Joan Capdevila Pujol
AU  - Benjamin Murray
AU  - Julia S El-Sayed Moustafa
AU  - Xinyuan Zhang
AU  - Richard Davies
AU  - Mario Falchi
AU  - Jonathan Wolf
AU  - Tim D. Spector
AU  - Andrew T. Chan
AU  - Sebastien Ourselin
AU  - Claire J. Steves
AU  - on behalf of the COPE Consortium
TI  - Key predictors of attending hospital with COVID19: An association study from the COVID Symptom Tracker App in 2,618,948 individuals
AID  - 10.1101/2020.04.25.20079251
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.25.20079251
4099  - http://medrxiv.org/content/early/2020/04/29/2020.04.25.20079251.short
4100  - http://medrxiv.org/content/early/2020/04/29/2020.04.25.20079251.full
AB  - Objectives We aimed to identify key demographic risk factors for hospital attendance with COVID-19 infection.Design Community surveySetting The COVID Symptom Tracker mobile application co-developed by physicians and scientists at King’s College London, Massachusetts General Hospital, Boston and Zoe Global Limited was launched in the UK and US on 24th and 29th March 2020 respectively. It captured self-reported information related to COVID-19 symptoms and testing.Participants 2,618,948 users of the COVID Symptom Tracker App. UK (95.7%) and US (4.3%) population. Data cut-off for this analysis was 21st April 2020.Main outcome measures Visit to hospital and for those who attended hospital, the need for respiratory support in three subgroups (i) self-reported COVID-19 infection with classical symptoms (SR-COVID-19), (ii) selfreported positive COVID-19 test results (T-COVID-19), and (iii) imputed/predicted COVID-19 infection based on symptomatology (I-COVID-19). Multivariate logistic regressions for each outcome and each subgroup were adjusted for age and gender, with sensitivity analyses adjusted for comorbidities. Classical symptoms were defined as high fever and persistent cough for several days.Results Older age and all comorbidities tested were found to be associated with increased odds of requiring hospital care for COVID-19. Obesity (BMI >30) predicted hospital care in all models, with odds ratios (OR) varying from 1.20 [1.11; 1.31] to 1.40 [1.23; 1.60] across population groups. Pre-existing lung disease and diabetes were consistently found to be associated with hospital visit with a maximum OR of 1.79 [1.64,1.95] and 1.72 [1.27; 2.31]) respectively. Findings were similar when assessing the need for respiratory support, for which age and male gender played an additional role.Conclusions Being older, obese, diabetic or suffering from pre-existing lung, heart or renal disease placed participants at increased risk of visiting hospital with COVID-19. It is of utmost importance for governments and the scientific and medical communities to work together to find evidence-based means of protecting those deemed most vulnerable from COVID-19.Trial registration The App Ethics have been approved by KCL ethics Committee REMAS ID 18210, review reference LRS-19/20-18210Competing Interest StatementZoe Global Limited developed the app with the guidance of clinicians. RD, JW, JCP, SG and JLduC work for Zoe Global Limited and TDS is a consultant to Zoe Global Limited.Funding StatementZoe Global Limited developed the app with the guidance of clinicians. Investigators received support from the Wellcome Trust, the MRC/BHF, Alzheimer’s Society, EU, NIHR, CDRF, and the NIHR-funded BioResource, Clinical Research Facility and BRC based at GSTT NHS Foundation Trust in partnership with KCL. ATC was supported in this work through a Stuart and Suzanne Steele MGH Research Scholar Award.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this study is available to bona fide researchers through UK Health Data Research using the following link https://healthdatagateway.org/detail/9b604483-9cdc-41b2-b82c-14ee3dd705f6 https://healthdatagateway.org/detail/9b604483-9cdc-41b2-b82c-14ee3dd705f6